These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25661440)

  • 1. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
    Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
    Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and future prospects of research on Fukuyama muscular dystrophy].
    Toda T
    Nihon Rinsho; 2015 Aug; 73(8):1425-36. PubMed ID: 26281700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice.
    Saito F; Kanagawa M; Ikeda M; Hagiwara H; Masaki T; Ohkuma H; Katanosaka Y; Shimizu T; Sonoo M; Toda T; Matsumura K
    Hum Mol Genet; 2014 Sep; 23(17):4543-58. PubMed ID: 24722207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
    Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
    PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
    Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
    Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
    Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
    J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.
    Yu M; He Y; Wang K; Zhang P; Zhang S; Hu H
    Hum Gene Ther; 2013 Mar; 24(3):317-30. PubMed ID: 23379513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
    Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
    Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
    Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
    Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
    Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective glycosylation of α-dystroglycan contributes to podocyte flattening.
    Kojima K; Nosaka H; Kishimoto Y; Nishiyama Y; Fukuda S; Shimada M; Kodaka K; Saito F; Matsumura K; Shimizu T; Toda T; Takeda S; Kawachi H; Uchida S
    Kidney Int; 2011 Feb; 79(3):311-6. PubMed ID: 20944549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
    Taniguchi-Ikeda M; Kobayashi K; Kanagawa M; Yu CC; Mori K; Oda T; Kuga A; Kurahashi H; Akman HO; DiMauro S; Kaji R; Yokota T; Takeda S; Toda T
    Nature; 2011 Oct; 478(7367):127-31. PubMed ID: 21979053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
    Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
    Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital muscular dystrophy with glycosylation defects of alpha-dystroglycan in Japan.
    Matsumoto H; Hayashi YK; Kim DS; Ogawa M; Murakami T; Noguchi S; Nonaka I; Nakazawa T; Matsuo T; Futagami S; Campbell KP; Nishino I
    Neuromuscul Disord; 2005 May; 15(5):342-8. PubMed ID: 15833426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fukutin and alpha-dystroglycanopathies.
    Toda T; Chiyonobu T; Xiong H; Tachikawa M; Kobayashi K; Manya H; Takeda S; Taniguchi M; Kurahashi H; Endo T
    Acta Myol; 2005 Oct; 24(2):60-3. PubMed ID: 16550916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies.
    Taniguchi M; Kurahashi H; Noguchi S; Fukudome T; Okinaga T; Tsukahara T; Tajima Y; Ozono K; Nishino I; Nonaka I; Toda T
    Hum Mol Genet; 2006 Apr; 15(8):1279-89. PubMed ID: 16531417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.